2,5-ditert-butylbenzo[d]oxazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: 2,5-ditert-butylbenzo[d]oxazole
• 英文别名: 2,5-Ditert-butyl-1,3-benzoxazole
• 化学式: C₁₅H₂₁NO
• 分子量: 231.338
• InChiKey: MLRJSQNNKAYYQA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  特戊胺 、 对叔丁基邻苯二酚 在 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 乙酸乙酯 为溶剂， 反应 5.0h， 以87%的产率得到2,5-ditert-butylbenzo[d]oxazole
  参考文献：
  名称：

  一种由儿茶酚类化合物和胺类化合物制备苯并噁唑类化合物的合成方法

  摘要：

  本发明提供了一种由儿茶酚类化合物和胺类化合物制备苯并噁唑类化合物的方法。该方法具有原料廉价易得、底物范围广、反应体系简单、所得目标产物易分离、反应操作简便、安全可靠等特点。与过渡金属催化的合成方法相比，该体系无需昂贵的金属催化剂和配体，降低了经济成本，避免了重金属对环境造成的污染以及金属在产物中的残留问题。该反应官能团耐受性较高，可用于合成一系列2‑芳基、三氟甲基、酯基、卤素、2‑烯基、2‑炔基、2‑烷基取代的苯并噁唑类衍生物，可用于含多种特殊官能团结构的苯并噁唑化合物，具有较大的应用价值。

  公开号：

  CN113264895B

文献信息

• SUBSTITUTED BENAMIDINES AS ANTIBACTERIAL AGENTS
  申请人：Haydon David John

  公开号：US20100298388A1

  公开（公告）日：2010-11-25

  Compounds of formula (IA) or (IB) have antibacterial activity: wherein W is ═C(H)— or ═N—; R 3 is a radical of formula -(Alk 1 ) m -(Z 1 ) p -(Alk 2 ) n -Q wherein m, p and n are independently 0 or 1, provided that at least one of m, p and n is 1 , Z1 is —O—, —S—, —S(O)—, —S(O 2 )—, —NH—, —N(CH 3 )—, —N(CH 2 CH 3 )—, —C(—O)—, —O—(C═O)—, —C(═O)—O—, or an optionally substituted divalent monocyclic carbocyclic or heterocyclic radical having 3 to 6 ring atoms; or an optionally substituted divalent bicyclic carbocyclic or heterocyclic radical having 5 to 10 ring atoms; Alk 1 and Alk 2 are optionally substituted C 1 -C 6 alkylene, C 2 -C 6 alkenylene, or C 2 -C 6 alkynylene radicals, which may optionally terminate with or be interrupted by —O—, —S—, —S(O)—, —S(O 2 )—, —NH—, —N(CH 3 )—, Or —N(CH 2 CH 3 )—; and Q is hydrogen, halogen, nitrile, or hydroxyl, or an optionally substituted monocyclic carbocyclic or heterocyclic radical having 3 to 6 ring atoms; or an optionally substituted bicyclic carbocyclic or heterocyclic radical having 5 to 10 ring atoms; R 4 and R 5 are optional substituents; and R 2 , R 6 and R 7 are independently hydrogen or a radical of formula -(Alk 3 ) x -(Z 2 )y-(Alk 4 ) z -H wherein x, y and z are independently 0 or 1, Z 2 is —O—, —S—, —S(O)—, —S(O 2 )—, —NH—, —N(CH 3 )—, —N(CH 2 CH 3 )—, —C(—O)—, —O—(C═O)— or —C(═O)—O—; Alk 3 and Alk 4 are optionally substituted C 1 -C 3 alkylene, C 2 -C 3 alkenylene, or C 2 -C 3 alkynylene radicals, which may optionally terminate with or be interrupted by —O—, —S—, —S(O)—, —S(O 2 )—, —NH—, —N(CH 3 )—, or —N(CH 2 CH 3 )—.

  化合物的结构式（IA）或（IB）具有抗菌活性：其中W为 ═C(H)— 或 ═N—；R3为具有以下结构的基团 -(Alk1)m-(Z1)p-(Alk2)n-Q，其中m、p和n独立地为0或1，但至少m、p和n中的一个为1，Z1为—O—、—S—、—S(O)—、—S(O2)—、—NH—、—N(CH3)—、—N(CH2CH3)—、—C(—O)—、—O—(C═O)—、—C(═O)—O—，或者具有3至6个环原子的可选择取代的一元环碳环或杂环基团；或者具有5至10个环原子的可选择取代的二元环碳环或杂环基团；Alk1和Alk2为可选择取代的C1-C6烷基、C2-C6烯基或C2-C6炔基基团，可能以—O—、—S—、—S(O)—、—S(O2)—、—NH—、—N(CH3)—、或—N(CH2CH3)—终止或中断；Q为氢、卤素、腈基或羟基，或者具有3至6个环原子的可选择取代的一元环碳环或杂环基团；或者具有5至10个环原子的可选择取代的二元环碳环或杂环基团；R4和R5为可选取代基团；R2、R6和R7独立地为氢或具有以下结构的基团 -(Alk3)x-(Z2)y-(Alk4)z-H，其中x、y和z独立地为0或1，Z2为—O—、—S—、—S(O)—、—S(O2)—、—NH—、—N(CH3)—、—N(CH2CH3)—、—C(—O)—、—O—(C═O)—或—C(═O)—O—；Alk3和Alk4为可选择取代的C1-C3烷基、C2-C3烯基或C2-C3炔基基团，可能以—O—、—S—、—S(O)—、—S(O2)—、—NH—、—N(CH3)—或—N(CH2CH3)—终止或中断。
• Inhibitors of Protein Tyrosine Kinase Activity
  申请人：METHYLGENE INC.

  公开号：US20130096136A1

  公开（公告）日：2013-04-18

  The present invention provides new compounds and methods for treating a disease responsive to inhibition of kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity of growth factor receptors, for example a disease responsive to inhibition of receptor type tyrosine kinase signaling, or for example, a disease responsive to inhibition of VEGF receptor signaling.

  本发明提供了用于治疗对激酶活性抑制产生反应的疾病的新化合物和方法，例如对蛋白酪氨酸激酶活性抑制产生反应的疾病，例如对生长因子受体蛋白酪氨酸激酶活性抑制产生反应的疾病，例如对受体型酪氨酸激酶信号抑制产生反应的疾病，或例如对VEGF受体信号抑制产生反应的疾病。
• SUBSTITUTED PHENYLPROPENYL PYRIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL APPLICATIONS
  申请人：SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD.

  公开号：US20210386721A1

  公开（公告）日：2021-12-16

  Disclosed are a substituted phenylpropenylpyridine derivative, a preparation method therefor and the use thereof as a PD-1/PD-L1 inhibitor. In particular, disclosed are a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, a preparation method therefor and the use thereof. The definition of each group in the formula is detailed in the description and claims.

  揭示了一种取代苯丙烯基吡啶衍生物，其制备方法以及其作为PD-1/PD-L1抑制剂的用途。具体地，揭示了一种符合式(I)的化合物或其药用可接受的盐、立体异构体、溶剂合物或前药，以及其制备方法和用途。公式中每个基团的定义在描述和权利要求中详细说明。
• Copolymerization and copolymers of aromatic polymers with carbon nanotubes and products made therefrom
  申请人：Hwang Wen-Fang

  公开号：US20070118937A1

  公开（公告）日：2007-05-24

  The present invention is generally directed to the block copolymerization of aromatic polymers with carbon nanotubes (CNTs), the CNTs typically being shortened, to form nanotube block copolymers. The present invention is also directed to fibers and other shaped articles made from the nanotube block copolymers of the present invention.

  本发明通常涉及芳香族聚合物与碳纳米管（CNTs）的块状共聚，通常缩短CNTs，以形成纳米管块状共聚物。本发明还涉及由本发明的纳米管块状共聚物制成的纤维和其他成型品。
• Diazepane Compounds Which Modulate The CB2 Receptor
  申请人：Cirillo Pier Francesco

  公开号：US20100261708A1

  公开（公告）日：2010-10-14

  Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

  公开了化学式（I）的化合物。发明的化合物与CB2受体结合并作为激动剂、拮抗剂或反向激动剂，对治疗炎症有用。那些作为激动剂的化合物还可用于治疗疼痛。